GILD

Gilead Sciences Stock (NASDAQ:GILD), Trade Ideas

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Woman,Shot,From,Above,Cutting,Paper,In,Half,With,The

News

Dividends

Price Target

Pre-Market Outlook

Markets

Trading Ideas

PDCO

Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Health Care Stocks Delivering High-Dividend Yields

Wall Street US stocks

Earnings

Equities

Futures

Previews

Economics

Federal Reserve

Movers

$BTC

CMCSA

GOOG

GOOGL

INTC

JNPR

KLAC

MBLY

MSFT

NDAQ

ORLY

ROKU

TDOC

TMUS

TSLA

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: &#39;Worst Of This Two-Week Decline Is Behind Us,&#39; Says Analyst

Cancer-Image by PDPics from Pixabay-

Biotech

Health Care

General

HOOK

RHHBY

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving significant milestones in collaboration and intellectual property.

Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.40%</li>
<li>Guggenheim analyst Vamil Divan initiated coverage on the stock with a Buy rating and a price target of $36 on Feb. 23, 2024. This analyst has an accuracy rate of 76%.</li>
<li>TD Cowen analyst Steve Scala downgraded the stock from Outperform to Market Perform with a price target of $32 on Jan. 4, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On April 24, Pfizer's board of directors declared a 42 cents second-quarter 2024 dividend on the company&#8217;s common stock.</li>
</ul>
<h3 class="wp-block-heading">Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li>Dividend Yield: 4.59%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $84 to $78 on March 4, 2024. This analyst has an accuracy rate of 76%.</li>
<li>RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and slashed the price target from $76 to $75 on Feb. 14, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Gilead Sciences is expected to release first quarter 2024 financial results on Thursday, April 25.</li>
</ul>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/04/38402061/jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner">Jim Cramer Says This Energy Stock Is &#8216;Terrific,&#8217; Calls Casey&#8217;s General Stores A &#8216;Winner&#8217;</a>

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) <a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding">lukewarm second-quarter revenue guidance </a>and commentary regarding investment punctured the stock, while International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) also fell on earnings. The tech space could come under pressure as traders digest these disappointments.
More tech earnings are on tap on Thursday, led by AI stalwart Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)
Also weighing down on sentiment would be apprehensions regarding two key data due for the week. The first read of the first-quarter GDP data (Thursday) and the personal income and spending report (Friday), will be in the spotlight as the market strives to make sense of growth and inflation trajectories ahead of next week&#8217;s Federal Reserve&#8217;s monetary policy meeting.
 Futures Performance On Thursday ( as of 5:50 a.m. EDT)
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.81%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.48%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.31%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.47%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> In <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noreferrer noopener">premarket</a>&nbsp;trading on Thursday, the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) slipped 0.43% to $503.24,&nbsp;and the&nbsp;Invesco QQQ ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.78% to $423.20, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.</figcaption></figure>
Cues From Past Session:
Early optimism triggered by positive reactions to earnings from Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Texas Instruments, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) tempered over the course of Wednesday&#8217;s session. Mixed earnings reports and economic worries kept sentiment subdued for much of the session, and this led to a mixed close for the day.
The tech-heavy Nasdaq Composite and the S&amp;P 500 Index ended the session marginally higher, pulling notably off the day&#8217;s high reached in early trading. The former moved in a roughly 205-point range and the latter gyrated between 5,047.02 and 5,089.48, a roughly 43-point intra-day move. Nevertheless, the indices have been higher for a third straight session now.
Weighed down by a 2.87% pullback in Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares following its earnings release, the Dow Jones Industrial Average ended modestly lower. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.10%</td>
<td>15,712.75</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.02%</td>
<td>5,071.63</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.11%</td>
<td>38,460.92</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.36%</td>
<td>1,995.43</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The growth conundrum of whether the economy is going to see a hard or soft landing, has kept investors skewed toward quality stocks, <a href="https://www.morganstanley.com/ideas/thoughts-on-the-market-wilson?subscribed=true&amp;dis=em_2024424_wm_5ideasarticle&amp;et_mid=585156&amp;et_mkid=&amp;sfmc_id=201810710">said </a>Morgan Stanley&#8217;s Chief Equity Strategist Mike Wilson in a podcast. &#8220;The largest risk for stocks more broadly is higher 10-year Treasury yields as investors begin to demand a larger term premium due to higher inflation and the growing supply of bonds to pay for the endless deficits,&#8221; he said.
&#8220;Our primary concern for equities at this point is that aggressive fiscal spending has led to better economic growth but it keeps upward pressure on inflation and prevents the Fed from cutting interest rates that many economic participants desperately need at this point.&#8221;
The analyst recommended investors look into under-appreciated sectors. &#8220;This is all in-line with our 2024 outlook that suggests the major equity indices are overvalued while the best opportunities are likely beneath the surface in underappreciated sectors like energy that are positively levered to stickier inflation and higher interest rates.&#8221;
Fund Strat&#8217;s Tom Lee, however, is optimistic. In his weekly commentary, the analyst noted that the S&amp;P 500 and equities rebounded over the past two days, rising more than 2%. &#8220;The S&amp;P 500 closed solidly above the critical 5,019.20 to 5,070.55. In our view, this is confirmation that the worst of this two-week decline is behind us,&#8221; he said.
Upcoming Economic Data:
The Bureau of Economic Analysis is due to release its<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/04/38405106/us-economy-expected-to-grow-2-5-in-q1-not-a-hard-landing-and-hardly-a-soft-one"> first-quarter GDP data (advance estimate) </a>at 8:30 a.m. EDT. Economists, on average, expect the economy to have expanded 2.2%, slower than the 3.4% pace in the fourth quarter. Traders may also keep an eye on the GDP price deflator and the price consumption expenditure index to gauge inflation trends.
The Labor Department will release the customary jobless claims data at 8:30 a.m. EDT. The number of individuals claiming unemployment benefits is expected at 215,000 for the week ended April 20, up slightly from 212,000 in the previous week.
The National Association of Realtors is scheduled to release its pending home sales index for March at 10 a.m. EDT, with consensus calling for an unchanged reading following the 1.6% increase in February.
The Treasury will auction four- and eight-week bills at 11:30 a.m. EDT and seven-year notes at 1 p.m. EDT.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures </a>
Stocks In Focus: 
<ul>
<li>Meta and IBM fell 12.5% and 8.5%, respectively, <a href="https://www.benzinga.com/premarket">in premarket trading </a>following quarterly earnings announcement.</li>
<li>Other stocks moving on earnings are ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) (down about 4.5%), Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) (up over 8%), O&#8217;Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) (down 4%), Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) (up over 12.5%), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) (up about 2.5%) and Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) (up about 2.5%).</li>
<li>Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), AstraZeneca Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Caterpillar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>), Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), Harley-Davidson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>), Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>), Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) and STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) are among the <a href="https://www.benzinga.com/calendars/earnings">companies reporting their earnings ahead of the market open.</a></li>
<li>Notable names reporting after the close include Alphabet, Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>), Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>), KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), Microsoft, Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>).</li>
</ul>
Commodities, Bonds, and Global Equity Markets:
Crude oil futures continued to trade under the $83-a-barrel mark and gold futures were seen consolidating just above the $2,330 level.
The 10-year note yield, held firm around the 4.64% ahead of Friday&#8217;s inflation data.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) weakened by about 3.50% and traded shy of the psychological barrier of $64,000.
Most major Asian markets, with the exception of the Chinese, Hong Kong and Indian markets, pulled back, as traders positioned themselves for Friday&#8217;s U.S. inflation data. The Australian and New Zealand markets remained closed for a public holiday.
The European markets fell in early trading, adding to the losses they made on Wednesday. The Euro STOXX 50 Index was down 0.44% at the last check.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/24/04/38410454/treasury-yields-reach-5-month-high-lift-mortgage-rates-expert-warns-federal-debt-">Treasury Yields Reach 5-Month High, Lift Mortgage Rates; Expert Warns &#8216;Federal Debt Blob Is Out Of Control&#8217;</a>
Image via Shutterstock

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst

HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Reduce to Hold and announces $69 price target.

Upgrades

Analyst Ratings

HSBC Upgrades Gilead Sciences to Hold, Announces $69 Price Target

Wednesday,&nbsp;HOOKIPA Pharma&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) received clearance from the FDA for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38399719/hookipa-pharma-announces-fda-clearance-of-its-investigational-new-drug-application-for-hb-700-for-" rel="noreferrer noopener">KRAS-mutated cancers</a>.
In January,&nbsp;Roche&nbsp;terminated the collaboration and licensing agreement for HOOKIPA&#8217;s HB-700 program in KRAS mutated cancers.&nbsp;
HOOKIPA&#8217;s HB-700 program&nbsp;is designed&nbsp;to treat KRAS-mutated lung, colorectal, pancreatic, and other cancers by targeting the five most prevalent KRAS mutations in these disease indications: G12D, G12V, G12R, G12C, and G13D.&nbsp;
The company says the program can benefit more patients than single mutation inhibitors.
The IND submission achieves a final $10 million milestone payment from&nbsp;Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>).
Effective April 25, 2024, the company will regain&nbsp;full&nbsp;control of the associated intellectual property portfolio and have full collaboration and licensing rights for the HB-700 program.&nbsp;
The company will publish preclinical data in an abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting.
&#8220;We are proud to have another IND cleared for a potentially powerful oncology program. Our HB-700 program targets five KRAS mutations found in multiple cancer indications with a single product candidate,&#8221; said Joern Aldag, Chief Executive Officer at HOOKIPA.&nbsp;
Earlier this year, HOOKIPA Pharma announced&nbsp;to focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and its two&nbsp;Gilead Science Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) -partnered infectious disease cure programs for hepatitis B and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36830043/roche-walks-away-from-hookipa-pharma-partnered-kras-focused-cancer-deal" rel="noreferrer noopener">human immunodeficiency virus</a>.
Price Action: HOOK shares are up 1.29% at $0.75 at the last check Wednesday.
Image by PDPics from Pixabay

As the <a href="https://www.benzinga.com/news/large-cap/24/04/38342737/nasdaq-100-notches-worst-day-since-late-2023-worst-week-since-late-2022-as-ai-driven-chipmakers-tu">market runs into rough weather,</a> the importance of the upcoming week&#8217;s earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (GOOG).
The Season So Far: The percentage of S&amp;P 500 companies that have reported positive earning surprises and the magnitude of earnings surprises are at or above their 10-year averages, <a href="https://insight.factset.com/sp-500-earnings-season-update-april-19-2024?utm_source=Direct&amp;utm_medium=Email&amp;utm_campaign=FO-04-19-2024&amp;utm_content=httpsinsightfactsetcomsp500earningsseasonupdateapril192024">said</a> FactSet in its report released Friday. That said, substantial downward revisions to earnings per share (EPS) estimates of two healthcare companies have led to a decline in earnings growth over the past two weeks.
The combined earnings per share growth rate of S&amp;P 500 companies, considering both the already reported actual results and the estimates for those yet to report, is at 0.5%, according to FactSet. The metric, however, fell from the 0.9% estimated previous week and the 3.4% estimated at the end of the first quarter. Earnings growth for the quarter may extend the positive growth streak to three quarters.
So far, 14% of the S&amp;P 500 companies have reported March quarter results. 
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best Tech Stocks To Buy Right Now</a>
Look Ahead: The upcoming week will likely feature earnings releases from 158 S&amp;P 500 companies, including 11 Dow 30 components. With the bank earnings tapering off, the spotlight shifts to tech companies, as they begin to roll out their quarterly scorecard this week.
Apart from some big techs, which are part of the group called the &#8220;Magnificent Seven,&#8221; homebuilders, defense contractors, airlines and transportation companies are also due to release their quarterly reports. 
All eyes are focused on Tesla as analysts expect a downbeat report from the company. Analysts see the scope of a further contraction in margin and potentially a double miss yet again in the first quarter.
AI stalwarts Microsoft, Alphabet and Meta are widely expected to report strong results. Following the recent tech-led sell-off, Wedbush analyst Daniel Ives said, &#8220;We believe 1Q earnings will be a major positive catalyst for the tech sector and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38252477/why-microsoft-alphabet-amazon-palantir-and-meta-could-rise-15-in-2024-according-to-">expect tech stocks to be up another 15% for the year</a> adding to the strong start to 2024.&#8221;
The earnings schedule of key names are as follows:
Monday 
<ul>
<li>Before the bell: Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Zions Bancorporation, National Association (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>)</li>
<li>After the close: Ameriprise Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) and SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>), Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)</li>
</ul>
Tuesday 
<ul>
<li>Before the bell: D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), General Motors Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>), Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), PepsiCo. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NYSE">PEP</a>), PulteGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>), Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) and Xerox Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NYSE">XRX</a>), Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) and Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)</li>
<li>After the close: Visa, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Texas Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), Tesla, Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>), Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Mattel, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>), Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), Canadian National Railway Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) and Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>)</li>
</ul>
Wednesday 
<ul>
<li>Before the bell: Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>), Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), Hasbro, Inc. (NASDA: HAS), General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), Biogen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) and AT&amp;T Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</li>
<li>After the close: Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>), Western Union Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>), O&#8217;Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Meta Platforms, Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)</li>
</ul>
Thursday 
<ul>
<li>Before the bell: Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), AstraZeneca Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Caterpillar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>), Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), Harley-Davidson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>), Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>), Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) and STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>)</li>
<li>After the close: Alphabet, Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>), Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>), KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), Microsoft, Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</li>
</ul>
Friday 
<ul>
<li>Before the bell: AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>), AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>), Barnes Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>), Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>)</li>
</ul>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the performance of the broader S&amp;P 500 Index, ended Friday&#8217;s session down 0.87% at $495.16, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data. </a>The ETF has pulled back from its all-time high (intraday) of $524.61 hit on March 28. The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), an ETF levered more to high-profile, non-financial tech companies, has lost 7.72% from its all-time intraday high of $449.34 (March 21).
Read Next: <a href="https://www.benzinga.com/news/large-cap/24/04/38342737/nasdaq-100-notches-worst-day-since-late-2023-worst-week-since-late-2022-as-ai-driven-chipmakers-tu">Nvidia In Correction Territory — Did AI-Led Tech Stock Bubble Just Burst? This Data Point Offers A Clue.</a>
Photo: Shutterstock

Analyst Color

Tech

ABBV

BIIB

CHTR

JBLU

LRCX

ODFL

SPOT

STLD

ZION

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

In the last three months, 12 analysts have published ratings on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $84.42, accompanied by a high estimate of $105.00 and a low estimate of $75.00. This current average represents a 5.15% decrease from the previous average price target of $89.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1713553233_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$82.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$84.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Unveiling the Story Behind Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
<h3>Understanding the Numbers: Gilead Sciences's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Gilead Sciences's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -3.72% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Gilead Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 20.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.33%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.3%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and maintains $105 price target.

Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price Target

Following an&nbsp;investigation&nbsp;announced in November last year, the FDA said on Thursday that it would now&nbsp;<a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed" rel="noreferrer noopener">require</a>&nbsp;boxed warnings—the highest safety-related caution for medications—for all chimeric antigen receptor (CAR) T-cell therapies.&nbsp;
According to the agency, these blood cancer treatments may pose a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">risk of secondary cancers</a>.
The health regulator has required related updates to other&nbsp;label sections, such as warnings and precautions, postmarketing experience, patient counseling information, and medication guides.
The agency said patients and clinical trial participants receiving treatment with these products should be monitored lifelong for secondary malignancies and notify the manufacturer in the event of a new malignancy.
In November, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35996543/eyes-on-novartis-gilead-bristol-myers-as-fda-weighs-risks-vs-benefits-of-approved-car-t-cell-ther" rel="noreferrer noopener">autologous CAR T cell immunotherapies</a>.
The agency said it&#8217;s weighing &#8220;the need for regulatory action&#8221; in response to clinical testing and safety monitoring reports tied to commercial use.&nbsp;
In&nbsp;January, the FDA asked drugmakers to add a boxed warning to their&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">CAR-T cancer therapies</a>.
In its January 19 notification letters, the agency stressed that the potential risk applies to all&nbsp;currently&nbsp;approved CAR-T products.&nbsp;
The regulatory body has mandated label updates for all six commercial CAR-T therapies, including&nbsp;Bristol Myers Squibb &amp; Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175623/download?attachment" rel="noreferrer noopener">Abecma</a>&nbsp;(partnered with partner&nbsp;2seventy bio&nbsp;Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsvt#NASDAQ">TSVT</a>))and&nbsp;<a target="_blank" href="https://www.fda.gov/media/175622/download?attachment" rel="noreferrer noopener">Breyanzi</a>,&nbsp;Johnson &amp; Johnson&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175624/download?attachment" rel="noreferrer noopener">Carvykti</a>&nbsp;(developed in partnership with&nbsp;Legend Biotech Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/legn#NASDAQ">LEGN</a>)),&nbsp;Novartis AG&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175625/download?attachment" rel="noreferrer noopener">Kymriah</a>, and&nbsp;Gilead Sciences Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175627/download?attachment" rel="noreferrer noopener">Yescarta</a>.
Gilead&#8217;s Tecartus was also part of the list, but later, it was removed from <a href="https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se" target="_blank" rel="noreferrer noopener">boxed warning requirements</a>.
Photo via Shutterstock

Large Cap

Penny Stocks

LEGN

TSVT

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $93,168, and 5 are calls, amounting to $211,849.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $75.0 for Gilead Sciences over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Gilead Sciences stands at 770.43, with a total volume reaching 765.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $65.0 to $75.0, throughout the last 30 days.
<h3>Gilead Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713460570_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.88</td>
<td>$2.76</td>
<td>$2.76</td>
<td>$75.00</td>
<td>$67.6K</td>
<td>1.8K</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.9</td>
<td>$4.75</td>
<td>$4.78</td>
<td>$67.50</td>
<td>$48.8K</td>
<td>174</td>
<td style="text-align: right;">31</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.05</td>
<td>$4.75</td>
<td>$4.79</td>
<td>$67.50</td>
<td>$44.3K</td>
<td>174</td>
<td style="text-align: right;">257</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.4</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$65.00</td>
<td>$42.5K</td>
<td>936</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$3.45</td>
<td>$3.3</td>
<td>$3.4</td>
<td>$67.50</td>
<td>$25.5K</td>
<td>83</td>
<td style="text-align: right;">215</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,746,138, the price of GILD is down by -1.33%, reaching $66.04.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Gilead Sciences</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $75.0.
<ul>
<li>Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Gilead Sciences, targeting a price of $75. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

What the Options Market Tells Us About Gilead Sciences

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return of 11.45%. Currently, Gilead Sciences has a market capitalization of $83.93 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $895.61 today based on a price of $67.31 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713378624_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Verve Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verv#NASDAQ">VERV</a>)</h3>
<ul>
<li>On April 2, Verve Therapeutics announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease. The treatment is supposed to permanently turn off a protein called PCSK9, which helps reduce blood cholesterol levels. The company&rsquo;s stock fell around 44% over the past month and has a <a href="https://www.benzinga.com/quote/VERV"> 52-week low of $7.36 </a>.</li>
<li>RSI Value: 25.88</li>
<li>VERV Price Action: Shares of Verve Therapeutics fell 8.5% to close at $8.01 on Wednesday.</li>
</ul>
<h3>UnitedHealth Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)</h3>
<ul>
<li>On April 10, TD Cowen analyst Gary Taylor maintained UnitedHealth with a Buy and lowered the price target from $607 to $546.. The company&rsquo;s stock fell around 8% over the past month. It <a href="https://www.benzinga.com/quote/UNH"> has a 52-week low </a> of $445.68.</li>
<li>RSI Value: 27.67</li>
<li>UNH Price Action: Shares of UnitedHealth fell 2.1% to close at $450.05 on Wednesday.</li>
</ul>
<h3>Gilead Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>)</h3>
<ul>
<li>On April 8, Gilead Sciences said it will release its first quarter 2024 financial results and guidance on Thursday, April 25, 2024, after the closing bell.. The company&rsquo;s stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/GILD"> low of $68.06.</a></li>
<li>RSI Value: 27.43</li>
<li>GILD Price Action: Shares of Gilead Sciences fell 2.6% to close at $68.12 on Wednesday.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38176517/how-to-earn-500-a-month-from-citigroup-stock-ahead-of-q1-earnings-report"> How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report</a>
<ul>
<li>&nbsp;</li>
</ul>
&nbsp;

Long Ideas

Small Cap

VERV

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/12/24</td>
<td>$114.00</td>
<td>$45.4K</td>
<td>14</td>
<td>1.3K</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$57.50</td>
<td>$231.0K</td>
<td>1.2K</td>
<td>568</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/12/24</td>
<td>$740.00</td>
<td>$92.6K</td>
<td>476</td>
<td>565</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$292.5K</td>
<td>2.3K</td>
<td>526</td>
</tr>
<tr>
<td>ANNX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$7.50</td>
<td>$113.0K</td>
<td>12.3K</td>
<td>505</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$152.50</td>
<td>$42.7K</td>
<td>2.2K</td>
<td>396</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$240.00</td>
<td>$82.9K</td>
<td>431</td>
<td>276</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$10.00</td>
<td>$25.3K</td>
<td>0</td>
<td>182</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$200.00</td>
<td>$25.0K</td>
<td>22</td>
<td>25</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$195.00</td>
<td>$26.1K</td>
<td>27</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 3 day(s) on April 12, 2024. This event was a transfer of 101 contract(s) at a $114.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $45.4K, with a price of $450.0 per contract. There were 14 open contracts at this strike prior to today, and today 1362 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a call option trade with bearish sentiment. It expires in 283 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $57.50 strike. The total cost received by the writing party (or parties) was $231.0K, with a price of $2310.0 per contract. There were 1271 open contracts at this strike prior to today, and today 568 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bearish, expiring in 3 day(s) on April 12, 2024. This event was a transfer of 299 contract(s) at a $740.00 strike. This particular put needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $92.6K, with a price of $310.0 per contract. There were 476 open contracts at this strike prior to today, and today 565 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option sweep that happens to be bullish, expiring in 283 day(s) on January 17, 2025. This event was a transfer of 500 contract(s) at a $70.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $292.5K, with a price of $585.0 per contract. There were 2303 open contracts at this strike prior to today, and today 526 contract(s) were bought and sold. 
• Regarding ANNX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>), we observe a call option sweep with bullish sentiment. It expires in 101 day(s) on July 19, 2024. Parties traded 481 contract(s) at a $7.50 strike. This particular call needed to be split into 39 different trades to become filled. The total cost received by the writing party (or parties) was $113.0K, with a price of $235.0 per contract. There were 12395 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a put option sweep that happens to be bullish, expiring in 10 day(s) on April 19, 2024. This event was a transfer of 196 contract(s) at a $152.50 strike. This particular put needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $42.7K, with a price of $218.0 per contract. There were 2200 open contracts at this strike prior to today, and today 396 contract(s) were bought and sold. 
• For COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on May 17, 2024. This event was a transfer of 143 contract(s) at a $240.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $82.9K, with a price of $580.0 per contract. There were 431 open contracts at this strike prior to today, and today 276 contract(s) were bought and sold. 
• Regarding NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we observe a put option trade with bearish sentiment. It expires in 192 day(s) on October 18, 2024. Parties traded 44 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $575.0 per contract. There were 0 open contracts at this strike prior to today, and today 182 contract(s) were bought and sold. 
• Regarding ALNY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on July 19, 2024. Parties traded 25 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $1000.0 per contract. There were 22 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a put option trade that happens to be bullish, expiring in 283 day(s) on January 17, 2025. This event was a transfer of 20 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $1306.0 per contract. There were 27 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

ANNX

EXAS

MRNA

NVAX

10 Health Care Stocks With Whale Alerts In Today's Session

Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one <a href="https://www.benzinga.com/quote/SBUX/news">such opportunity window.</a>
We looked at established companies that, recently, made new 52-week lows. We point readers&#8217; attention to three such stocks, with $35 billion market capitalizations. These are: Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Ambev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>).
<h2 class="wp-block-heading">Starbucks</h2>
Trading at around $86.83, the coffee franchise&#8217;s stock could potentially offer a buy-the-dip opportunity. The Seattle-based company&#8217;s shares command a market cap of over $98 billion on the stock market and sport an average three-month trading volume of 8.49 million.
The stock also offers, to its investors, a dividend yield of 2.63%.
Wells Fargo, TD Cowen, and TD Cowen released the last three analyst ratings on April 1, April 1, and March 19, 2024, respectively. These ratings suggest an average price target of $102.33 for Starbucks Corp, implying a potential upside of 17.23% based on the assessments of these three analysts.
Also Read: <a href="https://www.benzinga.com/insights/news/24/03/37971829/100-invested-in-this-stock-15-years-ago-would-be-worth-1-600-today">$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today</a>
<h2 class="wp-block-heading">Gilead Sciences</h2>
Trading at around $69.32, this biopharma stock is currently trading about its 52-week lows. The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, including medications such as Truvada, Atripla, and Descovy.
Gilead stock offers a robust dividend yield of 4.43%.
Wells Fargo, Mizuho, and Truist Securities recently released the last three analyst ratings. These assessments collectively suggest an average price target of $83.33 for Gilead stock.
Based on these ratings, there is an implied 20.16% upside potential for the company.
<h2 class="wp-block-heading">Ambev</h2>
Ambev SA is widely renowned for its portfolio of beer brands, including popular labels such as Skol, Brahma, Antarctica, and Budweiser. Trading at $2.40, Ambev stock is near-about its 52-week low level of $2.36. The stock also offers a juicy dividend yield of 6.26%.
Based on the analysis of the 8 latest analyst ratings, Ambev SA has a consensus price target of $2.2. The most recent ratings were issued by Barclays, Jefferies, and Bernstein on March 4, 2024, Nov. 22, 2023, and May 24, 2023, respectively. 
These assessments collectively indicate an average price target of $3.2 for Ambev stock. Consequently, there&#8217;s an implied 32.51% upside potential for the company based on these three analyst ratings.
These findings suggest that these quality stocks may present lucrative investment opportunities, offering potential upside for investors in the coming months.
Read Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38032100/redditors-identify-best-undervalued-stocks-for-2024">Redditors Identify &#8216;Best Undervalued Stocks&#8217; For 2024</a>

ABEV

SBUX

Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?

Xilio Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 19.9% Stake In The Co As Of March 27, 2024

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$460.00</td>
<td>$28.1K</td>
<td>580</td>
<td style="text-align: right;">917</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$115.00</td>
<td>$215.7K</td>
<td>1.4K</td>
<td style="text-align: right;">633</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$90.00</td>
<td>$352.0K</td>
<td>40</td>
<td style="text-align: right;">489</td>
</tr>
<tr>
<td>ESTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$52.50</td>
<td>$56.0K</td>
<td>1.3K</td>
<td style="text-align: right;">401</td>
</tr>
<tr>
<td>NVCR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$12.50</td>
<td>$35.0K</td>
<td>1.3K</td>
<td style="text-align: right;">374</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$82.50</td>
<td>$32.4K</td>
<td>325</td>
<td style="text-align: right;">351</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$195.00</td>
<td>$85.0K</td>
<td>1.0K</td>
<td style="text-align: right;">251</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/26/24</td>
<td>$70.00</td>
<td>$33.3K</td>
<td>56</td>
<td style="text-align: right;">142</td>
</tr>
<tr>
<td>INSP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$190.00</td>
<td>$34.8K</td>
<td>282</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$360.00</td>
<td>$68.2K</td>
<td>316</td>
<td style="text-align: right;">51</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 25 contract(s) at a $460.00 strike. The total cost received by the writing party (or parties) was $28.1K, with a price of $1125.0 per contract. There were 580 open contracts at this strike prior to today, and today 917 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 79 day(s) on June 21, 2024. Parties traded 500 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $215.7K, with a price of $431.0 per contract. There were 1484 open contracts at this strike prior to today, and today 633 contract(s) were bought and sold. 
• Regarding TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we observe a call option trade with bearish sentiment. It expires in 261 day(s) on December 20, 2024. Parties traded 275 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $352.0K, with a price of $1280.0 per contract. There were 40 open contracts at this strike prior to today, and today 489 contract(s) were bought and sold. 
• Regarding ESTA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>), we observe a call option trade with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 200 contract(s) at a $52.50 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $280.0 per contract. There were 1305 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• Regarding NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we observe a call option sweep with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 176 contract(s) at a $12.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $196.0 per contract. There were 1307 open contracts at this strike prior to today, and today 374 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be neutral, expiring in 653 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $82.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $550.0 per contract. There were 325 open contracts at this strike prior to today, and today 351 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bearish, expiring in 289 day(s) on January 17, 2025. This event was a transfer of 125 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $85.0K, with a price of $680.0 per contract. There were 1037 open contracts at this strike prior to today, and today 251 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option sweep with bullish sentiment. It expires in 23 day(s) on April 26, 2024. Parties traded 142 contract(s) at a $70.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $235.0 per contract. There were 56 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For INSP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>), we notice a put option sweep that happens to be bullish, expiring in 44 day(s) on May 17, 2024. This event was a transfer of 30 contract(s) at a $190.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.8K, with a price of $1160.0 per contract. There were 282 open contracts at this strike prior to today, and today 60 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 44 day(s) on May 17, 2024. This event was a transfer of 44 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $68.2K, with a price of $1550.0 per contract. There were 316 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESTA

INSP

NVCR

TMDX

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Equal-Weight and lowers the price target from $84 to $78.

CORRECTION: Wells Fargo On Mar. 4 Lowered Gilead PT From $84 To $78

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.26%. Currently, Gilead Sciences has a market capitalization of $90.11 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,009.64 today based on a price of $72.26 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712154634_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today

Contracts

NRIX

Gilead Sciences Extends Research Term By Two Years For Nurix Therapeutics' Deal, Announced In 2019, For $15M Extension Fee; Nurix Eligible For $73.5M In Preclinical Research Milestones And Licensing Fees, And $1.7B In Sales/Development Milestone

Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) to underperform, citing few <a href="https://www.benzinga.com/general/biotech/24/01/36474918/european-drugmaker-galapagos-collaborates-with-biotech-bridgene-biosciences-to-develop-cancer-tre" target="_blank" rel="noreferrer noopener">catalysts in the near term</a>.
Galapagos&#8217; enterprise value has been consistently low, ranging between $1.5 billion and $2 billion, and the analysts don&#8217;t anticipate any immediate or medium-term solutions to this.&nbsp;
Additionally, the company&#8217;s main programs are entering crowded markets where differentiation is unclear, and there is a lack of significant catalysts to drive growth.
Galapagos&#8217; primary cancer pipeline requires 3 to 4 years to reach the market, accompanied by significant cash depletion and uncertain standing in fiercely competitive markets.&nbsp;
Moreover, Galapagos&#8217; emphasis on acquiring early-stage assets increases the risk for investors, potentially leading to a decline in the stock price.&nbsp;
BofA Securities&#8217; downgrade to &#8220;Underperform&#8221; from &#8220;Neutral&#8221; is due to concerns that the stock may continue to be a value trap and underperform compared to its peers. The analyst lowered the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GLPG/analyst-ratings" rel="noreferrer noopener">price target from $41 to $31</a>.
Galapagos is currently conducting three early-stage trials to assess its autologous cell therapy (CAR-T) treatments for hematologic cancers.&nbsp;
The unique selling points of Galapagos&#8217; CAR-Ts lie in their potential differentiators:
<ul>
<li>Speed: Galapagos aims for a&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/g36499327/galapagos-enters-into-strategic-collaboration-agreement-with-thermo-fisher-scientific-to-further-e" rel="noreferrer noopener">swift 7-day manufacturing turnaround</a>&nbsp;time, quicker than the typical 30-day timeframe seen in most competitor programs. However, competitors like&nbsp;Gilead Sciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) are also working on reducing this time frame, with lymphoma programs reaching a 14-day turnaround and showing signs of improvement.</li>
<li>Supply: Galapagos has developed an automated manufacturing model that could eliminate some current production bottlenecks. However, being a late entrant (fifth) in most key markets poses a risk, as competitors may address supply issues before Galapagos can enter the market.</li>
</ul>
Thus, BofA sees a smaller commercial opportunity for Galapagos&#8217; CAR-T candidates and lower revenue forecasts by 15-25% in out-years (2028E+).
Price Action:&nbsp;GLPG shares are up 0.16% at $32.25 on the last check Monday.
Image: Shutterstock

Downgrades

GLPG

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?

3 Potential Biopharma Buyout Targets

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Today, several major companies are expected to report earnings: Altria Group (MO), Gilead Sciences (GILD), Alphabet Class A (GOOGL), Intel (INTC), ...

Options Volatility and Implied Earnings Moves Today, April 25, 2024

Polaris Global Equity Composite Q1 2024 Commentary

March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report) and Gilead Sciences (GILD – Res...

Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)